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The number of CD27++ plasma cells (PCs) in peripheral blood
may be a valuable biomarker for systemic lupus erythematosus
(SLE) disease management. More insights into the behavior of
the PC population are, however, required to validate CD27 as a
reliable biomarker. In the current study, we have monitored the
PC compartment of patients with acute bacterial infections and
patients with SLE and, in addition, examined the relationship
between the presence of serum antinuclear antibodies (ANAs)
and the number of peripheral PCs. Kinetic analyses in patients
with bacterial infection revealed a 10–60-fold expansion of the
CD27++ PC compartment that peaked at day 2–5 and returned
toward normal values at day 7–9 after hospital admission. The
transient expansion of the PC population appeared to be a late
phenomenon in the process of recovering from a bacterial infec-
tion.SLEsubjectshadsigniﬁcantlyincreasedfrequenciesofPCs
compared with patients suspected of a connective tissue disease
and healthy controls. In patients suspected of a connective tis-
sue disease, no relationship was found between the presence of
serum ANAs and the number of CD27++ PCs. Additionally, the
presence of serum ANAs was not associated with abnormalities
in other peripheral B-cell subsets. It remains to be established
at which stage of SLE development the expansion of the PC
compartment is initiated.
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INTRODUCTION
B lymphocytes continuously recirculate through periph-
eral blood and secondary lymphoid organs. B lympho-
cytes that encounter antigens become activated and dif-
ferentiate into antibody-producing plasma cells or, alter-
natively,becomememoryBcells.Thisprocessofantigen-
speciﬁcB-celldifferentiationoccurswithingerminalcen-
ters in secondary lymphoid organs, where activated na¨ ıve
B cells undergo vigorous proliferation, somatic hypermu-
tation of immunoglobulin (Ig) variable-region genes, Ig
isotype switching, and antigen-driven selection (1, 2).
The CD27 molecule belongs to the tumor necrosis
factor receptor family and is involved in the late-stage
differentiation of B cells by providing a key signal for
the maturation of B cells into plasma cells (PCs) (3–5).
On the basis of CD27 cell-surface expression peripheral
blood B cells can be divided into three different sub-
populations. CD27+ B cells carry somatically mutated
Ig variable genes and have been identiﬁed as memory B
cells. Na¨ ıve B cells that do not display such mutations are
deﬁned as CD27− (IgM+ IgD+) B cells (6–9). Peripheral
bloodBlymphocyteswithhighlevelsofCD27(CD27++)
were characterized as PCs, which express low levels of
CD19 and surface Ig, high amounts of CD38 and CD138,
and are CD20− (10–13). Disturbances in homeostasis of
speciﬁc peripheral blood B-cell subsets have been de-
scribed in patients with systemic autoimmune disorders.
Patients with systemic lupus erythematosus (SLE) exhibit
an expanded population of CD27++ PCs, while the num-
ber of CD27− na¨ ıve B cells is reduced (10, 12, 14, 15).
Analysis of peripheral blood from patients with primary
Sjogren’s syndrome and systemic sclerosis showed a pre-
dominance of CD27− na¨ ıve B cells and reduced frequen-
cies of CD27+ memory B cells compared with normal
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donors (15–17). Recently, an immature B-cell subpopu-
lation, so-called transitional B cells, has been identiﬁed
in peripheral blood (18). Increased frequencies of transi-
tional B cells, which are IgD+ CD38++, were observed in
patients with SLE and other autoimmune disorders such
as primary Sjogren’s syndrome (18–20). Connective tis-
sue diseases (CTD) are autoimmune diseases character-
ized by various organ manifestations and the production
of a broad variety of autoantibodies that are frequently
targeted against intracellular antigens of the cell nucleus
(i.e., antinuclear antibodies, ANAs) (21). Although B-
cell hyperreactivity and ANA production are characteris-
tic hallmarks of CTD, especially SLE, serum ANAs are
often found in subjects who do not fulﬁl the classiﬁcation
criteriaforaCTD(22).Recently,ithasbeendemonstrated
that ANAs are typically present many years before the di-
agnosisofSLE,whilepatientsarestillasymptomatic(23).
It is unknown whether the presence of serum ANAs coin-
cide with elevated frequencies of CD27++ PCs. Accurate
diagnosis and assessment of disease activity of SLE is
important to reduce morbidity and mortality. However, in
view of its heterogeneous presentation and unpredictable
course, clinical management of SLE is difﬁcult (24). The
frequencyofCD27++ PCshasbeenshowntosigniﬁcantly
correlate with SLE-disease activity: patients with active
SLE had higher frequencies of PCs than patients with
inactive SLE (12, 25). Hence, CD27 appears a promising
biomarker for monitoring SLE-disease activity. Addition-
ally, analyses of the CD27++ PC compartment may be
of diagnostic value in SLE. Insights into the behavior
of the PC compartment are essential to validate CD27
as a reliable biomarker for SLE. Indeed, polyclonal B-
cell activation due to infection could be considered as a
possible cause of CD27++ PC expansion. There is, how-
ever, a paucity of data on the behavior of the CD27++
PC compartment in a well-controlled immune response.
In the current study, the appearance and disappearance of
PCs in patients suffering from acute bacterial infection
were studied. Further, we have investigated whether the
presence of serum ANAs in subjects who do not fulﬁl
the classiﬁcation criteria for a CTD is associated with
abnormalities in B-lymphocyte subsets.
MATERIALS AND METHODS
Subjects and Blood Sampling
Blood samples of 120 consecutive patients suspected
of CTD (82 female, 38 male; mean age 48 years, range
18–66 years) and 30 clinically quiescent SLE patients (28
female, 2 male; mean age 50 years, range 24–75 years)
sent to the clinical laboratory for ANA assessment were
included. The control group consisted of 16 healthy blood
donors (14 female, 2 male; mean age 48 years, range
25–57 years). The patients were referred by inhouse spe-
cialists, including rheumatologists, internists, dermatolo-
gists, neurologists, and nephrologists. Clinical data were
obtained from the patient records. SLE was diagnosed ac-
cording to the American College of Rheumatology classi-
ﬁcation criteria (21, 26). Patients known with other types
of autoimmune diseases were excluded. Within the group
of patients suspected of CTD, six patients were treated
withimmunosuppressivedrugsatthetimeofanalysis(two
patients were receiving hydrochloroquine (200 mg/day),
threepatientswerereceivinglowdosesofprednisone(one
patient: 10 mg weekly; two patients 2.5–5.0 mg daily),
and one patient was being treated with 7.5 mg methorex-
ate weekly). The remaining CTD-suspected patients were
not receiving therapy. All six patients receiving immuno-
suppressive therapy had arthritis-like symptoms. Within
thepatientgroupofSLE,21patientsreceivedlowdosesof
prednisone (between 5 and 10 mg daily) and nine patients
were not receiving therapy. During the study, two newly
diagnosed SLE patients admitted to our hospital due to
an elevated disease activity were examined. One patient
was admitted due to abdominal pain and deep venous
thrombosis. Subsequently, an antiphospholipid antibody
syndrome and active nephritis were established. Further-
more, shortly (day 4) after hospital admission, the patient
developedamalarrashandleucocytopenia.Inserumhigh
titres of anti-ds DNA antibodies, antinuclear antibodies
and low levels of complement were detected. Immuno-
suppressivetherapyincludingtreatmentwithmethylpred-
nisolone (1000 mg for 3 days, thereafter 20 mg/day) and
mycophenolate mofetil (1000 mg twice daily) was started
4 weeks after admission. The second SLE patient was
admitted due to excessive polyarthritis. Furthermore, a
leucocytopenia, thrombocytopenia, elevated titres of anti-
ds DNA antibodies, serum antinuclear antibodies, circu-
lating immune complexes, and low levels of complement
wereestablished. Upon admission, thepatient wasreceiv-
ing low dosages of prednisone (5 mg/day). The patient’s
condition improved without increasing the dose of pred-
nisone or starting therapy with other immunosuppressive
agents.
A total of six patients with an acute bacterial infec-
tion admitted to the Emergency Department were moni-
tored for their plasma cell number in peripheral blood and
serum C-reactive protein (CRP) during their hospital stay.
All patients were treated with antibiotics upon admission.
Bloodwassampledfromanantecubitalveinbyvenipunc-
ture (Becton Dickinson Vacutainer, Meylan Cedex,
France). The study was approved by the ethical com-
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mittee of Sint Lucas Andreas Hospital, Amsterdam, The
Netherlands.
Immunoﬂuorescence Staining and Flow Cytometric
Analysis
Total white blood cell and lymphocyte count were per-
formed on an automated Bayer ADVIA 120 blood cell
counter (Bayer HealthCare, Tarrytown, NY, USA). Cell-
surface expression of CD markers on leukocytes was
analyzed by three-color immunoﬂuorescence cytometry
using a whole blood staining procedure as previously de-
scribed (27). Brieﬂy, 100 µL of EDTA anticoagulated
whole blood was incubated with peridinin chlorophyll
protein (PERC)-labeled anti-CD19 and ﬂuorescein isoth-
iocyanate(FITC)-labeledCD27incombinationwithphy-
coerythrin (PE)-labeled CD20, or CD138 monoclonal an-
tibodies (Becton Dickinson, San Jose, CA). Erythrocytes
were lysed with FACS-lysing solution (Becton Dickin-
son) according to the manufacturer’s instructions. Sam-
ples were washed with PBS/0.5% bovine serum albumin
and analyzed on a FACS-track cytometer (Becton Dick-
inson). Lymphocytes were gated on the basis of forward-
and right-angle scatter characteristics. For the detection
of CD27, CD20, and CD138 expressing B cells, a live
gate was set on the CD19+ cell population. Frequencies
of CD27++/CD20− PCs, CD27− na¨ ıve B cells, and IgD+
CD38++ transitional B cells of total CD19+ cells were
calculated using CellQuest software (Becton Dickinson).
Determination of ANA, Anti-ENA, and Anti-ds DNA
Antibodies
Assays for serum antinuclear antibodies were per-
formed by indirect immunoﬂuorescence with HEp-2000
cells according to the recommendations of the manu-
facturer (ImmunoConcepts, Sacramento, CA). Detection
of ANAs at a dilution of 1:40 was considered a posi-
tive result. Enzyme-linked immunosorbent assays were
used to evaluate the presence of serum antibodies to
SS-A, SS-B, RNP, Sm, Scl70, Jo-1, and histones (EliA,
Pharmacia Diagnostics, Freiburg, Germany). Antidouble-
stranded DNA antibodies were determined by FARR as-
say (Diagnostic Products Corporation, LA, USA).
Statistical Analysis
Statisticalanalyses were performedby usingSPSS ver-
sion 15.0 software. Nonparametric Mann–Whitney U test
was used to establish the level of signiﬁcance of differ-
encesbetweentwogroupsofsubjects.APvalueof <0.05
was considered statistically signiﬁcant.
RESULTS
Appearance and Disappearance of PCs During Bacterial
Infections and SLE
Sizes of the CD27++/CD20− PC compartment were
established in peripheral blood from patients with bac-
terial infection, SLE, and healthy controls. Furthermore,
the behavior of the PC compartment was monitored in the
group of patients with bacterial infection. In the healthy
control group, the mean frequency of CD27++/CD20−
PCs was 0.8 ± 0.1% (SD = 0.5%) and absolute num-
ber was 2.9 ± 0.8 106/L (SD = 3.3 106/L). Increased
mean frequencies of CD27++/CD20− PCs were found
in SLE patients (mean: 6.3 ± 1.1%) compared with the
control group (P < 0.001) (Fig. 1). The absolute number
of CD27++/CD20− PCs did not differ between SLE and
controls (P = 0.6). Since immunosuppressive therapy
may inﬂuence the presence of CD27++/CD20− PCs, the
relationship between immunosuppressive therapy and the
number of PCs was analyzed (12, 25). No differences
in either the frequency (P = 0.4) or absolute number
(P = 0.6) of PCs between SLE patients (N = 21) receiv-
ing immunosuppressive therapy and those who received
notherapy(N = 9)werefound.Similarly,norelationship
between immunosuppressive therapy and the number of
PCswasdetectedwithinthegroupofpatientssuspectedof
CTD (P = 0.8). During the study, two newly diagnosed
SLE patients exhibiting lupus ﬂare were examined. On
admission (day 0), both SLE patients had elevated fre-
quencies and absolute numbers of CD27++/CD20− PCs
(i.e., >2SDabovethemeanofcontrols)thatpersistedon
day 3 and 7 of hospitalization (Table I). One SLE patient
(patient #1) showed an increase in the number of PCs
at day 7 compared with day 3 that coincided with wors-
ening of the patient’s clinical condition (see the section
on Materials and Methods). After receiving intensive im-
munosuppressive therapy, a complete clinical remission
of SLE was reached. Analysis of PCs in blood from this
patient several months later showed a normal number of
CD27++/CD20− PCs (Table I and Fig. 2).
The clinical characteristics of the patients with acute
bacterial infection and the results of the PC analyses
are summarized in Tables II and III, respectively. Upon
hospital admission (day 0), patients with bacterial infec-
tion showed PC frequencies ranging from 0.5 to 5.6%.
At day 0, two out of six patients had an increased fre-
quency of PCs, i.e., CD27++ PCs >1.8% (>2 SD above
the mean of controls). The absolute number of PCs at
day 0 was moderately higher than controls (P = 0.03)
(Fig. 1). More interestingly, a marked increase in PC
number was detected during the ﬁrst days of hospital-
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Fig. 1. Box-and-whisker plot of frequencies (A) and absolute number
(B) of CD27++ plasma cells in peripheral blood from patients with
SLE (N = 30), patients suspected of connective tissue disease (ANA
negative, N = 75; ANA positive, N = 45), patients with bacterial
infection (N = 6) on day 0 and day 2–5 after hospital admission, and
healthy donors (controls, N = 16). The lower and upper limits of each
box represent the 25th and 75th percentile, respectively. The horizontal
bar within each box indicates the median. The whiskers emerging from
theboxesextendtotheupperandloweradjacentvaluesandaredeﬁnedas
values < 1.5 times the box height. Signiﬁcant differences from controls
are shown (∗P < 0.001,∗∗P = 0.03).
ization. The peak of expansion, which resulted in a 10–
60-fold increased PC-compartment size, was found be-
tween day 2 and 5 of hospitalization (Fig. 1). Between
day 7 and 9 of hospital admission, the frequency of PCs
returned toward normal values. As a representative, the
kinetic of the PC compartment from one septic patient
is shown in Fig. 3. Notably, the increase in PC number
was not related to the worsening of the clinical condi-
tion of the patients. All patients showed improved clinical
Table I. Follow-Up Analysis of CD27++ PCs in Peripheral Blood
from Two SLE Patients Admitted with Increased Disease Activity
Patient
Day(s) after
admission PCa (%) PC (×106/L)
1. 0 11.3 21.7
3 15.4 24.3
7 39.1 58.0
122 1.1 1.9
2. 0 9.4 15.2
3 8.0 14.5
7 7.1 13.8
aPC frequency of total CD19+ B lymphocytes.
conditions early on (day 0) after antimicrobiotic treat-
ment was initiated and recovered completely during their
hospital stay. In support, decreasing CRP levels were
found at the stage of expansion of the PC compartment
(Table III).
Relationship Between the Presence of Serum ANAs and
Sizes of B-Cell Compartments in CTD-Suspected Patients
The clinical characteristics of the group of CTD-
suspected patients are summarized in Table IV. Sizes
of IgD+ CD38++ transitional B cell, CD27− na¨ ıve B
cell, and CD27++/CD20− PC subpopulations were es-
tablished in peripheral blood of the patient groups and
control group. The mean frequency of CD27++/CD20−
PCs, CD27− na¨ ıve B cells, and IgD+ CD38++ tran-
sitional B cells in healthy controls was 0.8 ± 0.1%,
74 ± 2%, and 1.5 ± 0.2%, respectively. The observed
frequencies are consistent with prior reports (12, 15,
17, 18, 28). SLE patients showed increased frequencies
of CD27++/CD20− PCs (P<0.001) and IgD+ CD38++
transitional B cells (mean: 5.5 ± 1.1%, P = 0.01) com-
paredwithcontrols.Nodifferencesinabsolutenumbersof
CD27++/CD20− PCs (P = 0.6) and IgD+ CD38++ tran-
sitional Bcells (P = 0.1) between SLE and controls were
found.
In the group of patients suspected of CTD, the fre-
quency of CD27++/CD20− PCs was slightly increased
compared with controls (P = 0.03). The absolute num-
ber of CD27++/CD20− PCs did not differ from con-
trols (P = 0.06). Within the group of CTD-suspected
patients, patients with serum ANAs had similar fre-
quencies of CD27− na¨ ıve B cells (mean: 76 ± 2%
vs. 73 ± 2%, P = 0.4), IgD+ CD38++ transi-
tional B cells (mean: 2.3 ± 0.3% vs. 2.1 ± 0.2%,
P = 0.9), and CD27++ PCs (mean: 1.6 ± 0.2% vs.
2.0 ± 0.4%, P = 0.9) as patients without serum ANAs
(Fig. 1). These results indicate that the presence of serum
ANAs does not coincide with aberrant B-cell-subset
homeostasis.
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Table II. Clinical Characteristics of the Studied Patients with Bacterial Infection
Patient Sex Age (years) Results of culture Diagnosis
1. Female 55 Blood: Streptococcus pneumoniae Acute pneumonia
2. Female 26 Blood: Negative Acute pyelonephritis
Urine: Escherichia coli
3. Male 54 Respiratory tract: Streptococcus pneumoniae Acute pneumonia
4. Male 71 Blood: Streptococcus pyogenes Acute renal failure
5. Female 85 Joint ﬂuid: Streptococcus pyogenes Septic arthritis
Blood: Streptococcus pyogenes
6. Female 62 Respiratory tract: Streptococcus pyogenes Acute pneumonia
Blood: Negative
Table III. Percentage of CD27++ PCs in Peripheral Blood and Serum
CRP Levels of Patients with Bacterial Infection During Hospitalization
Patient
Day(s) after
admission PCa (%) CRP (mg/L)
1 0 0.5 426
1 1.2 450
3 5.0 192
72 . 1 2 7
91 . 1 3 5
2 0 2.1 389
1 4.0 219
2 5.5 198
4 12.6 88
5 15.6 50
11 2.8 6
3 0 1.0 616
1 4.3 523
2 45.4 324
4 63.1 162
85 . 0 7 2
4 0 5.5 449
1 6.9 413
2 14.8 327
3 49.4 216
5 20.5 93
73 . 1 3 8
5 0 5.6 339
2 35.1 273
5 16.8 45
85 . 0 6 7
93 . 0 5 8
60 0 . 5 1 3
10 . 6 6 7
2 0.5 325
4 11.6 68
72 . 5 1 7
aPC frequency of total CD19+ B lymphocytes.
Relationship Between the Presence of Serum Anti-ENA
Antibodies and Frequency of CD27++ Plasma Cells
ANA-positive serum samples were further analyzed
for identiﬁcation of the ﬁne-antigen speciﬁcity by anti-
ENA- and anti-ds DNA antibody testing. Within the
group of SLE patients, the presence of serum anti-
RNP antibodies (N = 13) was found to be associated
with a higher frequency of CD27++/CD20− PCs (mean:
Table IV. Prevalence of Clinical Manifestations of CTD-Suspected
Patients (N = 120)
Clinical manifestation %
Mucocutanous 14
Musculoskeletal 16
Serositis 5
Cardiovascular 2
Pulmonary 6
Gastrointestinal 19
Renal 9
Central nervous system 9
Hematologic 34
Others 6
8.5 ± 1.8%) compared with patients without these an-
tibodies (mean: 4.2 ± 0.8%, P = 0.02). Anti-dsDNA
(N = 9), anti-SS-A/B (N = 10), anti-SM (N = 4),
and antihistones (N = 14) antibodies were not found
to be related to a higher frequency of CD27++/CD20−
PCs (data not shown). In the group of CTD-suspected
patients, anti-ENA positivity was found in ﬁve cases.
No correlations between CD27-expressing B-cell sub-
sets and the occurrence of anti-ENA antibodies were
found. However, the small number of anti-ENA antibody-
positive patients did not allow conclusions of statistical
signiﬁcance.
DISCUSSION
The current study identiﬁes a characteristic pattern of
appearance and disappearance of PCs in peripheral blood
duringbacterialinfection.Patientsshowedatransient,10–
60-fold expansion of the PC compartment, that peaked at
day 2–5 after hospital admission. A wave of PCs in blood
hasalsobeenfoundinhumansaftersecondaryvaccination
with tetanus toxin. Large numbers of PCs were detectable
in blood on day 6 and 7 after immunization and disap-
peared from the blood after day 8 (29). There have been
no data reported on monitoring of the PC compartment
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during bacterial infections in humans. Earlier studies on
PCs have examined selected group of patients with reac-
tive plasmacytoses or in patients upon active secondary
immunizations (11, 29–32). The prior-examined patients
with reactive plasmacytoses had massive amounts of PCs
that are rarely seen during infection and inﬂammation
(11, 30, 33). One study established the number of PCs
in three patients with bacterial septicaemia and reported,
in agreement with our results, high amounts of PCs in
all patients (33). Additionally, we show that the PC ex-
pansion is transient and is a rather late phenomenon as
patients already showed clear clinical improvements with
decreasing CRP levels.
ThereisstrongevidencethatPCsgeneratedingerminal
centers during immune responses either remain within
the tissues of their origin or leave the secondary lym-
phoid organs and migrate via blood to the bone marrow,
mucosal-associated lymphoid tissue, or sites of inﬂam-
mation (34, 35). Hence, it is conceivable that the PCs
transiently present in blood during bacterial infections
are on their way to the bone marrow or other organs.
Plasma cell homing via blood to different tissues appears
to have a crucial role in regulating strength and dura-
tion of humoral immune responses. PCs predominantly
home to the bone marrow where they contribute to long-
term antibody production. In fact, the vast majority of
serum immunoglobulins produced are derived from bone
marrow PCs (36). Recent experiments have established
a key role for chemokines and their receptors expressed
on PCs in guiding the release of PCs from secondary
lymphoid organs and migration to their ﬁnal destination
(34, 35).
In SLE patients, we found disturbances of peripheral
B-cell homeostasis with accumulation of IgD+ CD38++
transitional B cells and CD27++ PCs. Our data, there-
fore, conﬁrm results reported by others (10, 12, 18, 20,
25). Elevated frequencies of CD27++ PCs, but no differ-
ences in absolute numbers between the clinically quies-
cent SLE patients and healthy controls were detected. In
support, others described that patients with inactive SLE
had increased frequencies of CD27++ PCs but normal
absolute numbers of PCs, whereas patients with active
SLE had elevated frequencies and absolute numbers of
PCs (12, 14). We found that patients with bacterial infec-
tions reached similar frequencies and absolute numbers
of CD27++ PCs as previously reported in active SLE pa-
tients (12, 14). Patients with SLE are known to be more
susceptible to common and opportunistic infections due
to immunologic defects and immunosuppressive therapy
(37). Therefore, in case CD27 is chosen as a biomarker
for monitoring SLE-disease activity, infections should be
considered as a possible cause of CD27++ PC increase.
However, the kinetic of PC expansion between infection
and active SLE may differ. In support, we found that two
newly diagnosed SLE patients admitted to our hospital
due to an elevated disease activity had strongly elevated
CD27++ PC numbers that persisted during their hospi-
tal stay. One patient reached a clinically quiescent status
of SLE after intensive immunosuppressive therapy that
coincided with a marked reduction of PC number. Ac-
cordingly, others have reported a decline in frequency of
PCs after effective immunosuppressive therapy of an SLE
patient (12).
Since virtually all SLE patients have ANAs in their
serum, this triggered us to investigate the association be-
tween the presence of ANAs and B-cell subset home-
ostasis. The presence of serum ANAs appeared not to
be associated with abnormalities in the distribution of
speciﬁc B-cell subpopulations within the group of CTD-
suspected patients. Thus, the presence of serum ANAs
itself does not coincide with increased numbers of IgD+
CD38++ transitional B cells and CD27++ PCs as char-
acteristically seen in SLE patients. These ﬁndings may
indicate that autoantibody production is not preceded by
accumulation of CD27++ PCs. Our preliminary results
suggest that the presence of antibodies against RNP is re-
lated with increased frequencies of CD27++ PCs in SLE.
A weak relationship between the number of CD27++ PCs
and the occurrence of anti-ENA antibodies was also ob-
served in a prior study (25). In contrast to our data, in
the prior study, anti-SS-A/B and anti-dsDNA antibodies
were found to be associated with increased CD27++ PC
frequencies (25). The discrepancy may be due to differ-
ences in level of disease activity of the studied patients or
differences in assays used for detection of these type of
antibodies.
The majority of included CTD-suspected patients had
clinical and laboratory features suggestive for SLE but,
however, did not fulﬁl the classiﬁcation criteria for SLE.
These patients had signiﬁcantly lower frequencies of
CD27++ PCs compared with SLE patients suggesting
a possible diagnostic value of PC analyses in SLE.
Autoantibodies are present many years before the onset
of SLE, while patients are still asymptomatic, and are
believed to contribute directly to the pathogenesis of
SLE (23). Our results may indicate that disturbances
in homeostasis in B-cell subsets is a phenomenon
that appears in more advanced, pathogenic stages of
development of SLE and is not yet present at the stage of
antinuclear antibody production. Additional studies are
needed to further validate the suitability of PC analysis
as a diagnostic tool for SLE. For instance, it remains to
be established at which developmental stage of SLE PCs
start to accumulate in peripheral blood.
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